BioretecOHEL:BRETEC FCF Yield % is -36.03 as of Jul. 12, 2026. The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Bioretec ranks worse than 89.12% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Bioretec's FCF Yield % or its related term are showing as below:
OHEL:BRETEC'
s FCF Yield % Range Over the Past 10 Years
Min: -258.39 Med: -7.08 Max: -0.64
Current: -36.03
During the past 8 years, the highest FCF Yield % of Bioretec was -0.64%. The lowest was -258.39%. And the median was -7.08%.
OHEL:BRETEC's FCF Yield % is ranked worse than 89.12% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.42
vs OHEL:BRETEC: -36.03
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bioretec FCF Yield % Related Terms
Bioretec FCF Yield % Historical Data
* Premium members only.
The historical data trend for Bioretec's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OHEL:BRETEC vs ABT, SYK, MDT: FCF Yield % Comparison
For the Medical Devices subindustry, Bioretec's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioretec FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioretec's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Bioretec's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioretec (OHEL:BRETEC) has a FCF Yield % of -36.03 as of Jul. 12, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bioretec and its competitors. According to the industry distribution chart, Bioretec ranks #762 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 89.1%.
Is Bioretec's FCF Yield % too high?
Bioretec's current FCF Yield % is -36.03. Based on the distribution chart, Bioretec ranks #762 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Bioretec's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioretec ranks #762 out of 855 companies for FCF Yield %. This places Bioretec in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Bioretec and its competitors. Bioretec's current FCF Yield % is -36.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (OHEL:BRETEC) is currently considered Possible Value Trap. The stock's GF Value™ is €0.19, compared to a current price of €0.02 — trading 88.7% below its estimated fair value. The current FCF Yield % is -36.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Bioretec (OHEL:BRETEC), the current FCF Yield % is -36.03 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OHEL:BRETEC has been successfully added to your 